BACKGROUND: Mesenchymal stem cells (MSCs) represent a potential useful source for cell-based glioma therapies because these cells evidence both orthodox and unorthodox plasticity and also show tropism for cancer. In this study, the authors attempted to access the cytotoxicity of human umbilical cord blood (hUCB)-derived MSCs, with or without cytokine activations against malignant glioma cells. MATERIALS AND METHODS: hUCB-derived MSCs were activated by interleukin-2, interleukin-15, granulocyte macrophage colony-stimulating factor, and combinations. The hUCB-derived MSCs and activated hUCB-derived MSCs were effector cells. The cytotoxicity of the unactivated hUCB-derived MSCs and activated hUCB-derived MSCs against the target cells (human malignant glioma cells) was estimated via visual survival cell assays and transwell inserts. Phenotypic changes occurring in these hUCB-derived MSCs before and after cytokine activation were determined via flow cytometry. The secreted proteins from these effector cells were estimated via enzyme-linked immunosorbent assays. RESULTS: We noted a significant cytotoxicity of hUCB-derived MSCs against malignant glioma cells. In addition, the hUCB-derived MSCs activated with cytokines evidenced significantly higher cytotoxicity than that observed with unactivated hUCB-derived MSCs. Differentiated immune effectors cells from the hUCB-derived MSCs after cytokine activation were not shown to have increased in number. However, the activated hUCB-derived MSCs secreted more immune response-related proteins (interleukin 4, interferon-gamma) than did the unactivated hUCB-derived MSCs. CONCLUSION: The data collected herein confirm for the first time that hUCB-derived MSCs, with or without activation, evidence significant cytotoxicity against human malignant glioma cells, and the immune response-related proteins secreted in this process may perform relevant functions.
BACKGROUND: Mesenchymal stem cells (MSCs) represent a potential useful source for cell-based glioma therapies because these cells evidence both orthodox and unorthodox plasticity and also show tropism for cancer. In this study, the authors attempted to access the cytotoxicity of human umbilical cord blood (hUCB)-derived MSCs, with or without cytokine activations against malignant glioma cells. MATERIALS AND METHODS: hUCB-derived MSCs were activated by interleukin-2, interleukin-15, granulocyte macrophage colony-stimulating factor, and combinations. The hUCB-derived MSCs and activated hUCB-derived MSCs were effector cells. The cytotoxicity of the unactivated hUCB-derived MSCs and activated hUCB-derived MSCs against the target cells (humanmalignant glioma cells) was estimated via visual survival cell assays and transwell inserts. Phenotypic changes occurring in these hUCB-derived MSCs before and after cytokine activation were determined via flow cytometry. The secreted proteins from these effector cells were estimated via enzyme-linked immunosorbent assays. RESULTS: We noted a significant cytotoxicity of hUCB-derived MSCs against malignant glioma cells. In addition, the hUCB-derived MSCs activated with cytokines evidenced significantly higher cytotoxicity than that observed with unactivated hUCB-derived MSCs. Differentiated immune effectors cells from the hUCB-derived MSCs after cytokine activation were not shown to have increased in number. However, the activated hUCB-derived MSCs secreted more immune response-related proteins (interleukin 4, interferon-gamma) than did the unactivated hUCB-derived MSCs. CONCLUSION: The data collected herein confirm for the first time that hUCB-derived MSCs, with or without activation, evidence significant cytotoxicity against humanmalignant glioma cells, and the immune response-related proteins secreted in this process may perform relevant functions.
Authors: Annick Desjardins; Jennifer A Quinn; James J Vredenburgh; Sith Sathornsumetee; Allan H Friedman; James E Herndon; Roger E McLendon; James M Provenzale; Jeremy N Rich; John H Sampson; Sridharan Gururangan; Jeannette M Dowell; August Salvado; Henry S Friedman; David A Reardon Journal: J Neurooncol Date: 2007-01-24 Impact factor: 4.130
Authors: Seok-Gu Kang; Sin Soo Jeun; Jung Yeon Lim; Do Sung Yoo; Pil Woo Huh; Kyung Souk Cho; Dal Soo Kim; Hyung-Jin Shin; Jong Hyun Kim; Moon Chan Kim; Joon Ki Kang Journal: Childs Nerv Syst Date: 2005-06-03 Impact factor: 1.475
Authors: K S Aboody; A Brown; N G Rainov; K A Bower; S Liu; W Yang; J E Small; U Herrlinger; V Ourednik; P M Black; X O Breakefield; E Y Snyder Journal: Proc Natl Acad Sci U S A Date: 2000-11-07 Impact factor: 11.205
Authors: Gaurav D Shah; Joel S Silver; Steven S Rosenfeld; Igor T Gavrilovic; Lauren E Abrey; Andrew B Lassman Journal: J Neurooncol Date: 2007-06-27 Impact factor: 4.130
Authors: Antonella Scheda; Janvier Kaba Finjap; Jochen Tuettenberg; Marc Alexander Brockmann; Andreas Hochhaus; Ralf Hofheinz; Frank Lohr; Frederik Wenz Journal: Tumori Date: 2007 Jan-Feb
Authors: Tobias Birnbaum; Julia Roider; Christoph J Schankin; Claudio S Padovan; Christian Schichor; Roland Goldbrunner; Andreas Straube Journal: J Neurooncol Date: 2007-02-14 Impact factor: 4.506
Authors: Vera S Donnenberg; Ludovic Zimmerlin; Joseph Peter Rubin; Albert D Donnenberg Journal: Tissue Eng Part B Rev Date: 2010-11-02 Impact factor: 6.389
Authors: Isabele C Iser; Stefanie M Ceschini; Giovana R Onzi; Ana Paula S Bertoni; Guido Lenz; Márcia R Wink Journal: Mol Neurobiol Date: 2015-12-19 Impact factor: 5.590
Authors: Christopher S Gondi; Venkateswara R Gogineni; Chandramu Chetty; Venkata R Dasari; Bharathi Gorantla; Meena Gujrati; Dzung H Dinh; Jasti S Rao Journal: Int J Oncol Date: 2010-05 Impact factor: 5.650